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H E A L T H  A N D  M E D I C I N E
Hepatocyte-specific HIF-1 ablation improves  
obesity-induced glucose intolerance by reducing  
first-pass GLP-1 degradation
Yun Sok Lee1*, Matthew Riopel1, Pedro Cabrales2, Guatam K. Bandyopadhyay1
The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. 
In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1 
expression was increased mainly by soluble factors released from obese adipocytes, leading to decreased incretin 
effects. Deletion of hepatocyte HIF-1 protected obesity-induced glucose intolerance without changes in body 
weight, liver steatosis, or insulin resistance. In-depth mouse metabolic phenotyping revealed that obesity increased 
first-pass degradation of an incretin hormone GLP-1 with increased liver DPP4 expression and decreased sinusoidal 
blood flow rate, reducing active GLP-1 levels in peripheral circulation. Hepatocyte HIF-1 KO blocked these changes 
induced by obesity. Deletion of hepatocyte HIF-2 did not change liver DPP4 expression but improved hepatic 
steatosis. Our results identify a previously unknown pathway for obesity- induced impaired beta cell glucose response 
(incretin effects) and the development of glucose intolerance through inter-organ communications.
INTRODUCTION
The etiology of type 2 diabetes mellitus (T2DM) involves both insulin 
resistance and  cell dysfunction, and one typically needs both 
defects to develop the hyperglycemic diabetic state (1, 2). It has been 
suggested that reciprocal interaction between these two defects may be 
able to contribute to progressive deterioration of glucose homeostasis 
by increasing body insulin needs and hyperinsulinemia, exaggerating 
 cell stress and insulin resistance (1–3). However, whether insulin 
target tissues communicate with pancreatic  cells and cause  cell 
dysfunction is not clearly understood.
Incretins are peptide hormones produced from enteroendocrine 
cells in the gastrointestinal (GI) tract (4, 5). Glucose or mixed meal 
ingestion stimulates incretin secretion, and increased circulating 
incretins bind to their specific receptors on the surface of  cells, 
potentiating glucose-stimulated insulin secretion. In healthy hu-
mans, incretin action is responsible for approximately 60 to 70% of 
postprandial insulin secretion (6). However, in obesity, incretin ef-
fects are decreased even before onset of T2DM and decline further 
as the disease progresses with unknown mechanisms (7). Thus, in 
T2DM subjects, incretin effects account for only 7 to 40% of post-
prandial insulin secretion (8, 9).
Most incretin effects are mediated by two gut hormones: glucagon- 
like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP) (4, 5). Systemic effects of these incretin hormones 
are controlled mainly at the levels of secretion and inactivation. 
Once released, circulating incretins are rapidly inactivated by the 
specific peptidase enzyme dipeptidyl peptidase-4 (DPP4) (10) and 
are eventually cleared, mainly by the kidney (11). DPP4 is produced 
as a membrane-bound protein, and a soluble circulating form of 
DPP4 is generated through proteolytic cleavage at the base of the 
extracellular domain (12). DPP4 is expressed ubiquitously but most 
abundantly in the GI tract, kidney, liver, and endothelial cells (13).
GLP-1 is one of the most studied gut hormones fulfilling incretin 
criteria. GLP-1 enhances glucose-stimulated insulin secretion and 
suppresses glucagon secretion, whereas GIP stimulates secretion of 
both insulin and glucagon (14). GLP-1 is targeted by DPP4 with an 
in vivo half-life of 1.5 to 2 min (15). Consequently, only 10 to 15% 
of the secreted intact/active GLP-1 enters the systemic circulation 
(16). Global knockout (KO) of DPP4 causes six- to ninefold increases 
in plasma intact/active GLP-1 levels and improves glucose tolerance 
in mice (13, 17). Therefore, it is plausible that DPP4-dependent 
GLP-1 inactivation may be a critical regulatory step for systemic GLP-1 
action. In T2DM, circulating levels of intact/active GLP-1 are de-
creased (5, 9, 18, 19), whereas GIP levels are increased (14). More-
over, the effect of exogenous GLP-1 to increase insulin secretion is 
diminished in subjects with impaired glucose tolerance (IGT) or T2DM 
(20) with increased plasma DPP4 activity compared to normal (21). 
Therefore, it appears that the decrease of intact/active GLP-1 levels 
is an important etiologic component of decreased incretin effects 
(insulin secretion) and glucose tolerance in obesity and T2DM (22). 
Administration of a long-acting GLP-1 receptor agonist or DPP4 
inhibitor compounds improves glycemic control in type 2 diabetics. 
Increased adiposity and insulin resistance are associated with this 
defect (23); however, the mechanisms for how obesity decreases intact/
active GLP-1 levels are unknown.
In the present study, we adopted interdisciplinary approaches to 
assess obesity-induced changes in hepatic microhemodynamics and 
DPP4 activity. We found that obesity increased hepatic hypoxia- 
inducible factor–1 (HIF-1), leading to decreased sinus oidal blood 
flow rate and velocity, and increased DPP4 expression. These changes 
were sufficient to augment first-pass degradation of incretin hormones.
RESULTS
Obesity increases hepatic HIF-1 expression
High-fat diet (HFD) induces progressive deterioration of glucose 
intolerance with decreased insulin sensitivity and impaired glucose- 
stimulated insulin secretion in mice (24). This is similar to the clin-
ical manifestations observed in subjects with IGT (1, 2). HIF-1 is 
an intracellular oxygen sensor and plays a crucial role in regulating 
hepatic glucose and lipid metabolism in normal and pathological 
conditions (25). Increased liver HIF-1 promotes liver damage, steatosis, 
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and inflammation in a rodent model of alcoholic steatohepatitis 
(26). Moreover, liver HIF-1 overexpression induces lipogenic and 
gluconeogenic pathways (27–29). To examine the effect of obesity 
on liver oxygen homeostasis, we measured the expression of HIF-
1 and HIF-2 in the liver of normal chow diet (NCD) and HFD 
mice. Protein expression of HIF-1 and mRNA levels of HIF-1 target 
genes such as Vegf, Pdk1, and Lox were increased in HFD mouse 
liver compared with NCD-fed control mice (Fig. 1, A and B). On 
the other hand, HIF-2 protein levels and mRNA expression of sev-
eral HIF-2–specific target genes, such as Epo, Cat, Cited2, and Irs2, 
were not increased in obese mouse liver (Fig. 1, A and B), suggest-
ing that diet-induced obesity confers isoform-selective regulation of 
hepatic HIF- protein expression.
Deletion of hepatocyte HIF-1 improves glucose tolerance
To assess the effects of HIF-1 in obesity-associated liver dysfunction, 
we generated hepatocyte-specific HIF-1 KO (HHKO) mice (Hif1afl/fl: 
Albumin-Cre+) (Fig. 1, C and D) and measured their metabolic pheno-
type on NCD and HFD. Cre− Hif1a-floxed mice (Hif1afl/fl:Albumin-Cre−) 
did not show significant changes in liver Hif1a and Epas1/Hif2a expres-
sion, plasma insulin levels, or glucose tolerance on NCD and HFD 
compared with age-matched wild-type (WT) mice. Therefore, Cre− 
Hif1a-floxed littermates were used as controls, referred to hereafter as WT 
for comparison with HHKO mice. HHKO mice exhibited normal body 
weight, liver and adipose tissue mass, and hepatic vascular density on 
both NCD and HFD (Fig. 1, E to G, and fig. S1). On NCD, HHKO mice 
exhibited normal oral glucose tolerance (Fig. 1H). However, on HFD, 
HHKO mice displayed significantly improved oral glucose tolerance 
compared to controls (Fig. 1H).
Hepatocyte HIF-1 is not necessary for obesity-induced liver 
steatosis, inflammation, and insulin resistance
To test whether the improvement of glucose tolerance in HFD HHKO 
mice is associated with improved insulin sensitivity, we performed 
insulin tolerance tests and calculated homeostatic model assessment for 
insulin resistance (HOMA-IR). Unexpectedly, insulin tolerance and 
Fig. 1. Increased hepatic HIF-1 expression contributes to glucose intolerance in obesity. (A) Liver HIF- expression (n = 3 mouse per group). (B) mRNA levels of HIF 
target genes in liver (n = 6 mice per group). Epo was barely expressed in NCD and HFD mouse liver (Ct > 30) with high variability in its expression. *P < 0.05, **P < 0.01, 
***P < 0.001. (C) Liver Hif1a and Epas1/Hif2a mRNA levels (n = 6, 4, 11, and 8 mice per group). **P < 0.01 versus lane 3, ##P < 0.01 versus lane 1. (D) mRNA levels of Hif1a in 
primary hepatocytes isolated from HFD mice (n = 4 mice per group). **P < 0.01. (E) Body weight (BW) (n = 6, 4, 11, and 8 mice per group). (F) Immunohistochemistry anal-
ysis of CD31-positive vascular density in liver sections (n = 4 NCD WT, 4 NCD HHKO, 11 HFD WT, and 10 HFD HHKO mice). Images were taken under ×200 magnification. 
*P < 0.05 versus lane 1. (G) Liver mass of HFD mice (n = 11 and 8 mice per group). (H to J) Metabolic phenotyping of HHKO mice. NCD and HFD WT and HHKO mice were 
subjected to oral glucose tolerance tests (OGTTs) (H) or intraperitoneal insulin tolerance tests (IPITTs) (J). HOMA-IR (I) was calculated from the data collected during OGTT. 
n = 6, 4, 11, and 8 mice were used per group. *P < 0.05, **P < 0.01 HFD WT versus KO; ##P < 0.01 versus lane 1. AUC, area under the curve; AU, arbitrary units. Similar results 
were observed in at least two separate cohort mouse studies. For statistical analysis, one-way (C; F; and H, right) or two-way (H, left) analysis of variance (ANOVA) with post 
hoc t tests between the individual groups or two-tailed unpaired t test (B and D) was performed. All data are presented as means ± SEM.
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HOMA-IR were not changed in HFD HHKO mice compared with 
HFD WT mice (Fig. 1, I and J). Moreover, plasma and liver levels of 
triglycerides and nonesterified fatty acids, histologic features of hepatic 
steatosis, and mRNA expression of lipogenic Fas were all comparable 
in HFD WT and HHKO mice (fig. S2, A to F). Furthermore, mRNA 
expression of proinflammatory Tnfa and fibrogenic Lox, Acta2 [encoding 
alpha smooth muscle actin, (-SMA)], and Tgfb1 was comparable in 
the liver of WT and HHKO mice (fig. S2G), while obesity-induced 
hepatic caspase-3/7 activity and serum alanine transferase activity 
were reduced in HHKO mice (fig. S2, H and I). Consistent with this, 
the ratio of Kupffer cells (KCs), recruited hepatic macrophages (RHMs), 
and T and B lymphocytes in overall CD45+ hepatic leukocyte popu-
lation was identical in HFD WT and HHKO mice (fig. S2, J to L). 
Moreover, proinflammatory gene expression in each of the KC or 
RHM fractions was comparable between the genotypes (fig. S2M). 
Together, these results suggest that, unlike alcohol-induced hepatic 
disease (26), hepatocyte HIF-1 expression is not necessary for obesity- 
induced liver steatosis or inflammation.
Deletion of hepatocyte HIF-1 improves glucose tolerance 
by increasing GLP-1 action
Because HFD HHKO mice exhibited improved glucose tolerance 
without changes in insulin sensitivity, we went on to test whether 
insulin secretion is increased in HHKO mice. As seen in Fig. 2 (A to C), 
HFD HHKO mice exhibited higher HOMA-% index with higher 
plasma insulin and C-peptide levels upon high glucose challenge. 
This occurred without changes in pancreas mass, overall pancreatic 
insulin content, and  cell mass (Fig. 2, D to F). Moreover, insulin–
to–C-peptide ratio was comparable between HFD WT and HHKO 
mice (Fig. 2G). These results suggest that HHKO improved obesity- 
induced glucose intolerance mainly by increasing  cell insulin 
secretion, without changes in insulin sensitivity,  cell mass, or plasma 
insulin clearance.
To test whether increased  cell insulin secretion in HHKO 
mice is associated with increased incretin action, we first measured 
intraperitoneal glucose tolerance (IPGTT), which does not stimu-
late incretin secretion. As seen in Fig. 2H, intraperitoneal glucose 
tolerance was comparable between HFD WT and HHKO mice. More-
over, glucose-stimulated plasma active GLP-1 and active GIP levels 
were significantly higher in HFD HHKO mice compared with HFD 
WT mice (Fig. 2, I and J). Plasma total GLP-1 levels were unchanged 
(Fig. 2I). To test whether improved oral glucose tolerance in HFD 
HHKO mice was mainly due to increased active GLP-1 levels, we 
injected the GLP-1 receptor antagonist exendin-9 (ex9) to HFD WT 
and HHKO mice and measured oral glucose tolerance. As seen in 
Fig. 2K, ex9 treatment impaired glucose tolerance in both HFD WT 
and HHKO mice. Consequently, oral glucose tolerance became 
comparable in HFD WT and HHKO after ex9 administration 
(Fig. 2K). Together, these results suggest that HHKO increased  cell 
insulin secretion and improved glucose tolerance by increasing 
circulating active GLP-1 levels.
Deletion of hepatocyte HIF-1 decreases glucagon 
sensitivity by increasing GLP-1 action
Increased glucagon action is an important cause of hyperglycemia, 
especially in insulin-resistant states such as T2DM (30). GLP-1 also 
contributes to glucose homeostasis by suppressing glucagon secretion 
and action through both insulin-dependent and insulin-independent 
mechanisms (31, 32). To test whether increased plasma active GLP-1 
levels in HHKO mice led to a decrease in hepatic glucagon sensitivity, 
we performed glucagon tolerance tests with or without ex9 treat-
ment. As seen in Fig. 2L, HFD HHKO mice exhibited decreased 
glucose excursion upon intraperitoneal glucagon challenge com-
pared with HFD WT controls. Ex9 treatment increased glucagon- 
stimulated glucose excursion in both HFD WT and HHKO mice, 
and after ex9 administration, glucagon tolerance was identical in HFD 
WT and HHKO mice (Fig. 2M). Serum glucagon levels were slightly 
decreased in HHKO mice, but this did not reach statistical significance 
(Fig. 2N). Together, these results suggest that, in obesity, increased 
hepatocyte HIF-1 contributes to increased glucagon sensitivity mainly 
by decreasing GLP-1 action.
Beyond its insulinotropic effects, GLP-1 exerts direct effect on 
hepatocyte metabolism (33–35). Consistently, we observed that GLP-1 
treatment decreased glucose production in cultured primary hepatocytes 
(Fig. 2O), with decreased glucagon-stimulated cyclic AMP (adenosine 
monophosphate) levels. To test whether the local hepatic GLP-1 
effect is increased in HHKO mice in a quantitative fashion, we con-
ducted hyperglycemic clamp studies (Fig. 2P). GLP-1 increases plasma 
insulin levels by enhancing glucose-stimulated insulin secretion, as 
well as by decreasing plasma GLP-1 clearance (36). Therefore, 
to block both insulin secretion and action and measure insulin- 
independent hepatic GLP-1 effects, we gave mice a constant infusion 
of somatostatin and S961 insulin receptor antagonist along with 
exogenous glucagon ± GLP-1. Basal hepatic glucose production 
(HGP) was comparable in HFD WT and HHKO mice (Fig. 2Q). 
Infusion of active GLP-1 increased the glucose infusion rate with 
decreased HGP in both HFD WT and HHKO mice, but these effects 
of GLP-1 were enhanced in HHKO mice compared with WT mice 
(Fig. 2, R to T).
Obesity promotes first-pass GLP-1 degradation through 
HIF-1–dependent regulation of liver DPP4 expression 
and sinusoidal blood flow rate
The increase in plasma intact/active GLP-1 levels without changes 
in total GLP-1 levels in HFD HHKO mice raises a possibility that 
HHKO decreases GLP-1 inactivation. Because GLP-1 inactivation 
is mediated mainly by DPP4 (13), we assessed the effect of obesity 
and hepatocyte HIF-1 KO on systemic and hepatic DPP4 expres-
sion. As seen in Fig. 3A and fig. S3 (A and B), Dpp4 expression was 
increased selectively in liver and adipose tissue but not in the kidney 
or GI tract of obese mice. DPP4 protein expression and activity were 
also increased in both liver and serum of obese WT mice (Fig. 3, B  
and C, and fig. S3C). When measured separately, obesity increased 
DPP4 expression specifically in hepatocytes, but not in nonparen-
chymal hepatic cells, although Dpp4 was abundantly expressed in 
both hepatocytes and nonparenchymal hepatic cells (Fig. 3, D and E). 
In HHKO mice, serum and liver DPP4 expression or activity or 
liver Dpp4 mRNA levels were not increased in obesity (Fig. 3, A to F). 
While increased in obesity, adipose tissue Dpp4 expression was neg-
ligible compared with liver Dpp4 expression and was not affected in 
HHKO mice (figs. S3D and S4A).
HFD/obesity also increased hepatocyte DPP4 release (Fig. 3G), with 
increased expression of hepatic DPP4 sheddases (metalloprotease-1 
and metalloprotease-14) (fig. S4B) (37). However, the increase of DPP4 
expression was very large in HFD hepatocytes so that the fraction 
of DPP4 that is released was lesser in hepatocytes from HFD mice 
(Fig. 3H). HIF-1 KO did not affect the proportion of released DPP4 
among the total intracellular DPP4 or the expression of DPP4 sheddases 
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(Fig. 3H and fig. S4B). Immunohistochemistry analyses revealed that 
DPP4 protein was largely localized to the plasma membrane of HFD/obese 
hepatocytes (Fig. 3I), suggesting that obese liver is highly accumulated 
with membrane-bound DPP4 on the plasma membrane of hepatocytes.
Newly produced active GLP-1 is first introduced into the sys-
tem through the portal circulation, and previously, it was reported that 
hepatic GLP-1 extraction accounts for ~44% of exogenous GLP-1 degra-
dation (38). Therefore, we hypothesized that the HIF-1–dependent 
Fig. 2. HHKO mice exhibit improved glucose tolerance by increasing plasma incretin levels and insulin secretion. (A to C) Plasma insulin (B) and C-peptide (C) 
levels during OGTT in Fig. 1H mice were used for calculating HOMA-% (A). #P < 0.05, *P < 0.05 versus WT counterparts. (D to F) Pancreas mass (D), pancreatic insulin 
content (E), and overall  cell mass (F) were measured in NCD and/or HFD WT and HHKO mice. n = 6 NCD WT, 4 NCD HHKO, 11 HFD WT, and 8 HFD HHKO mice. (G) Plasma 
insulin/C-peptide ratio in Fig. 1H mice. (H) IPGTTs. n = 11 and 10 per group. (I and J) Plasma total (I, left) and active GLP-1 (I, right) and active GIP (J) levels in 6-hour–fasted 
HFD WT and HHKO mice before or 10 min after glucose oral gavage (n = 5 and 7 mice per group). *P < 0.05 versus WT controls. (K) OGTTs in HFD mice conducted 30 min 
after saline or ex9 administration. n = 11 and 10 per group. *P < 0.05, HFD WT + saline versus HFD HHKO + saline. (L and M) Glucagon (Gcg) tolerance tests with (M) or 
without (L) ex9 administration 30 min before glucagon injection. n = 6 and 7 per group. *P < 0.05. (N) Fasting (6 hours) serum glucagon levels (n = 6, 10, and 8 mice per 
group). *P < 0.05 versus lane 1. (O) Gluconeogenesis activity assays in primary hepatocytes. n = 5 wells per group. §P < 0.05 versus NCD group in lane 2, *P < 0.05 versus 
HFD group in lane 1, #P < 0.05 versus HFD group in lane 2. (P) Schematic representation of the experimental procedures for hyperglycemic clamp studies in (Q) to (T). (Q to 
T) Hyperglycemic clamp studies. Basal HGP (Q), glucose infusion rate (GIR) (R), clamped HGP (S), and %suppression of HGP (T) were calculated as described in Materials 
and Methods. n = 5, 4, 9, and 7 mice per group. *P < 0.05 versus lane 2, #P < 0.05 versus lane 1, ##P < 0.01 versus lane 1. For statistical analysis, one-way (A, N, O, and R to T) 
or two-way (B, C, I, J, and L) ANOVA with post hoc t tests between the individual groups was performed. All data are presented as means ± SEM.
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increase in membrane-bound DPP4 expression in obese liver could 
enhance first-pass GLP-1 inactivation. A premise of this hypothesis is 
that obesity does not increase sinusoidal blood flow rate or velocity 
because it can decrease retention time of intact/active GLP-1 within 
liver before escaping to systemic blood circulation. Therefore, we as-
sessed liver microhemodynamics in NCD and HFD WT and HHKO 
mice. Blood flow rate across liver was not increased but decreased in 
HFD/obese WT mice compared with NCD/lean WT mice (Fig. 3J). 
Moreover, sinusoidal blood flow rate, velocity, and pressure as well as 
sinusoidal diameter were substantially decreased in HFD WT mice 
compared with NCD WT mice (Fig. 3K). These changes were more 
pronounced at arteriolar/portal venular (A/PV) sinusoids than central 
venular (CV) sinusoids (Fig. 3K). Moreover, in HFD mice, the ratio of 
sinusoidal blood pressure gradient over blood flow was increased at 
A/PV sinusoids compared with NCD mice without changes in that at 
CV sinusoids. These results suggest that HFD/obesity increases 
sinusoidal flow resist ance. Consistent with this idea, portal vein blood 
pressure was substantially increased in HFD mice compared with NCD 
mice (Fig. 3L). These changes in hepatic microcirculation were associ-
ated with increased liver Edn1 (encoding endothelin-1, a vasoconstrictor) 
expression (Fig. 3M). Moreover, the levels of extracellular adenosine, a 
purine metabolite producing vasodilation, were decreased in cultured 
HFD WT mouse hepatocytes, with increased adenosine deaminase 
(ADA) activity in the plasma membrane fraction of the cells compared 
with NCD WT mouse hepatocytes (Fig. 3, N and O). Consistently, 
mRNA expression of Ada was increased by HFD (fig. S4C).
Fig. 3. Deletion of hepatocyte HIF-1 blocks obesity-induced liver DPP4 expression and first-pass GLP-1 inactivation. (A to C) Liver Dpp4 mRNA (A) and liver (B) 
and serum (C) DPP4 protein levels (n = 6, 4, 11, and 8 mice per group). *P < 0.05 versus lane 3, ##P < 0.01 versus lane 1. (D) Dpp4 mRNA expression in primary hepatocytes 
(Hep) and nonparenchymal cells (NPC) isolated from NCD and HFD WT mice (n = 4 mice per group). **P < 0.01 versus lane 1. (E) DPP4 protein content in primary hepato-
cytes isolated from NCD and HFD WT mice (n = 4 and 6 mouse per group). ###P < 0.001 versus lane 1, ***P < 0.001 versus lane 3. (F) Dpp4 mRNA expression in primary he-
patocytes isolated from HFD WT and HHKO mice (n = 11 and 8 mice per group). **P < 0.01. (G) DPP4 protein release from cultured primary hepatocytes (n = 4 and 6 mouse 
per group). ###P < 0.001 versus lane 1, ***P < 0.001 versus lane 3. (H) Relative DPP4 release per hepatocyte DPP4 content (n = 4 and 6 mouse per group). ###P < 0.001. 
(I) Immunohistochemistry analysis of DPP4 in the liver of NCD and HFD WT and HHKO mice. Images were taken under ×400 magnification. (J) Blood flow rate across liver 
(n = 4 mice per group). *P < 0.05. DAPI, 4′,6-diamidino-2-phenylindole. (K) Liver microhemodynamics (n = 4 mice per group). **P < 0.01, ***P < 0.001. (L) Portal vein blood 
pressure (n = 4 mice per group). *P < 0.05, **P < 0.01. (M) Liver Edn1 mRNA expression (n = 6 NCD WT, 4 NCD KO, 11 HFD WT, and 8 HFD KO mice per group). **P < 0.01, 
***P < 0.001. (N) Extracellular adenosine levels (n = 4 different mouse hepatocytes per group). *P < 0.05, **P < 0.01. (O) ADA activity in the plasma membrane fraction of 
hepatocytes (n = 4 different mouse hepatocytes per group). **P < 0.01, ***P < 0.001. (P) Intact/active GLP-1 levels in the portal and cardiac plasma of 6-hour–fasted mice 
before or 10 min after glucose oral gavage (n = 18 NCD WT, 19 HFD WT, 6 NCD HHKO, and 10 HFD HHKO mice). *P < 0.05, **P < 0.01, ***P < 0.001; N.S., not significant. For 
statistical analysis, one-way ANOVA (A to C, E, G, H, and K to P) with post hoc t tests between the individual groups or two-tailed unpaired t test (D, F, and J) was performed. 
All data are presented as means ± SEM.
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In HHKO mice, sinusoidal blood flow rate, velocity, and pres-
sure as well as sinusoidal diameter were not decreased upon HFD 
and were higher than those in HFD WT mice (Fig. 3K). These changes 
were associated with lower Edn1 and Ada expression in HFD HHKO 
mice compared with HFD WT mice (Fig. 3M and fig. S4C). More-
over, extracellular adenosine levels were higher in the conditioned 
media of HFD HHKO mouse hepatocytes compared with those of 
HFD WT mouse hepatocytes, along with decreased ADA activity in 
the plasma membrane fraction (Fig. 3, N and O). Consistently, 
treatment with a HIF-1 stabilizing agent, CoCl2, increased Edn1, 
Ada, and Dpp4 mRNA expression in WT hepatocytes but not in 
HIF-1 KO hepatocytes (fig. S4D). On the other hand, expression 
of Entpd1 and Nt5e encoding the enzymes important for extracellular 
adenosine generation (CD39 and CD73) was unchanged in HFD 
HHKO mice compared with HFD WT mice (fig. S4C). These results 
suggest that obesity-induced hepatocyte HIF-1 can promote sinusoi-
dal vasoconstriction and flow resistance by increasing endothelin-1 
expression and decreasing extracellular adenosine levels, causing 
decreased sinusoidal blood flow rate.
Last, we tested whether these HIF-1–dependent changes in 
sinusoidal blood flow and liver DPP4 expression in obesity led to 
increased first-pass GLP-1 degradation. To this end, we measured 
active GLP-1 levels in the portal and peripheral (cardiac) plasma of 
6-hour–fasted NCD and HFD mice before and 10 min after high 
glucose challenge. As expected, upon fasting, intact/active GLP-1 
levels were comparable in the portal and peripheral plasma (Fig. 3P). 
Upon glucose challenge, plasma active GLP-1 levels were increased 
in both portal and cardiac plasma in all mice (Fig. 3P). Moreover, 
intact/active GLP-1 levels were substantially higher in the portal 
plasma compared with peripheral plasma, consistent with the view 
that hepatic GLP-1 elimination is induced upon high glucose chal-
lenge. In NCD WT mice, glucose-stimulated plasma active GLP-1 
levels were ~56% lower in peripheral plasma compared with portal 
plasma (Fig. 3P, lane 2 versus lane 10). In HFD/obese mice, this 
difference was increased to ~76% (Fig. 3P, lane 4 versus lane 12), 
suggesting that obesity causes ~35% increase in first-pass GLP-1 
inactivation.
On NCD, intact/active GLP-1 levels were comparable in WT and 
HHKO mice in both portal and peripheral plasma (Fig. 3P, lane 10 
versus lane 14). However, on HFD, HHKO mice exhibited signifi-
cantly increased glucose-stimulated peripheral plasma intact/active 
GLP-1 levels (Fig. 3P, lane 12 versus lane 16) without changes in the 
portal plasma intact/active GLP-1 levels (Fig. 3P, lane 4 versus lane 8). 
This led to ~67% increase in peripheral active GLP-1 levels in HFD 
HHKO mice compared with HFD WT mice. These results suggest 
that deletion of hepatocyte HIF-1 led to a decrease in glucose- 
stimulated first-pass intact/active GLP-1 degradation by preventing 
obesity-induced liver DPP4 expression.
Hepatocyte HIF-2 does not regulate liver DPP4 expression
Both HIF-1 and HIF-2 can be induced in hypoxic conditions and 
mediate hypoxic responses with many common target genes. How-
ever, distinct or opposite physiological roles of HIF-1 and HIF-2 
have also been reported in certain (patho-)physiological contexts 
including obese adipocytes (25, 39–41). In liver, it was reported that 
HIF-2 overexpression improves glucose and glucagon tolerance 
and hepatic insulin sensitivity (40, 42). Therefore, we hypothesized 
that hepatic HIF-2 can counteract HIF-1, at least functionally, like 
in adipocytes (39). To address this question in the context of obe-
sity, we generated hepatocyte-specific HIF-2 KO (H2HKO) mice 
(Hif2afl/fl:Albumin-Cre+) (Fig. 4A) and measured their metabolic phe-
notypes. Cre− Hif2a-floxed littermates (Hif2afl/fl:Albumin-Cre−) 
were used as WT controls for H2HKO mice. Unexpectedly, H2HKO 
mice exhibited normal body weight gain (Fig. 4B) and comparable 
glucose and insulin tolerance compared with WT mice on both 
NCD and HFD (Fig. 4, C to E). Moreover, glucagon tolerance was 
also unchanged in HFD H2HKO mice compared with HFD WT 
controls (Fig. 4F). Consistent with this, plasma and hepatic DPP4 
protein levels and mRNA expression of hepatic Dpp4 and Irs2 were 
also unchanged in H2HKO mice (Fig. 4, G to I). These results sug-
gest that hepatocyte HIF-2 is dispensable for the maintenance of 
normal glucose and insulin tolerance and for the development of 
glucose, glucagon, and insulin intolerance in obesity. On the other 
hand, HFD H2HKO mice exhibited lower levels of hepatic triglyceride 
and nonesterified fatty acid content with decreased expression of 
lipogenic Fas compared with HFD WT controls (Fig. 4, I to K), sug-
gesting that hepatocyte HIF-2 expression contributes to obesity- 
induced hepatic steatosis. These results are consistent with a previous 
report that deletion of Hif2a/Epas1 improves liver steatosis in Von 
Hippel-Lindau (VHL) KO background in mice (43).
Adipose tissue dysfunction induces liver HIF-1  
and Dpp4 expression
Next, we sought to identify the mechanism for how obesity confers 
increased liver HIF-1 expression. Previously, we and others reported 
that HFD/obesity decreases oxygen tension in adipose tissue (44, 45), 
and this leads to increased adipocyte HIF-1 expression, triggering 
adipose tissue inflammation and dysfunction (3, 39, 46, 47). Consist-
ent with previous reports, adipose tissue oxygen tension was de-
creased in HFD mice (fig. S5A). Interstitial oxygen tension was also 
moderately reduced in the liver but not in the skeletal muscle and 
kidney of HFD WT mice compared with NCD controls (Fig. 5A and 
fig. S5, A and B). To test whether this moderate decrease in hepatic 
interstitial oxygen tension is sufficient to induce hepatocyte HIF-1 
expression, we incubated primary mouse hepatocytes at various ox-
ygen conditions, including 2 and 3% oxygen equivalent to the inter-
stitial oxygen tension in the liver of lean and obese mice, respectively 
(Fig. 5A). As seen in Fig. 5B and fig. S5 (C and D), Hif1a mRNA and 
protein levels were not different at 2 and 3% oxygen conditions. These 
results suggest that the obesity-induced decrease in hepatic intersti-
tial oxygen tension is not severe enough to trigger increased hepato-
cyte HIF-1 expression. In contrast, HIF-2 levels were slightly lower 
at 2% compared with 3% oxygen condition (Fig. 5B).
Next, we turned our attention toward signaling pathways that 
can stimulate HIF-1 expression in hepatocytes. Incubation of primary 
hepatocytes with different combinations of hormones and nutrients 
that are commonly increased in obesity revealed that leptin, insulin, 
fructose, and high levels of palmitic acid and glucose can interac-
tively increase hepatocyte HIF-1 expression (Fig. 5C and fig. S5E). 
Among these, the combination of leptin + palmitic acid was suffi-
cient to induce maximal HIF-1 expression. Moreover, leptin + 
palmitic acid treatment stimulated Dpp4, Edn1, and Ada expression 
in culture hepatocytes, which was blunted in HIF-1 KO hepato-
cytes (Fig. 5D and fig. S5F). In sharp contrast, HIF-2 expression 
was decreased by the combination of leptin + palmitic acid + insulin 
(Fig. 5C). To test whether increased plasma leptin concentrations 
are critical for obesity-induced hepatic HIF-1 expression, we in-
jected anti-leptin–neutralizing antibodies into HFD/obese mice. As 
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seen in Fig. 5E, acute neutralization of circulating leptin markedly 
decreased hepatic HIF-1 expression.
Plasma levels of an insulin-sensitizing hormone, adiponectin, 
are decreased in obesity, and adiponectin counteracts leptin in certain 
physiological contexts (48). Therefore, we tested whether decreased 
plasma adiponectin levels can also contribute to the increase in liver 
HIF-1 expression in obesity. As seen in Fig. 5F (lane 2 versus lanes 
9 to 12), increasing adiponectin concentrations markedly reduced 
leptin-stimulated hepatocyte HIF-1 expression. Moreover, adi-
ponectin treatment decreased leptin-induced Dpp4 expression in 
hepatocytes (Fig. 5G). Further mechanistic studies revealed that 
leptin stimulated mammalian target of rapamycin (mTOR) phos-
phorylation in hepatocytes, and inhibition of mTOR activation by 
pretreatment with rapamycin blocked leptin-stimulated HIF-1 expres-
sion (Fig. 5F). Moreover, adiponectin suppressed leptin-stimulated 
phosphorylated mTOR levels (Fig. 5F). These results suggest that leptin 
stimulates HIF-1 expression through an mTOR-dependent signaling 
pathway, and adiponectin counteracts it. Together, these results suggest 
that increased plasma leptin and free fatty acids (FFAs) and decreased 
adiponectin levels are associated with increased liver HIF-1 expression.
Because leptin and adiponectin are adipocyte-specific hormones 
and the increase in plasma FFA levels in obesity is mainly due to 
increased lipolysis in adipose tissue, these results suggest that adi-
pose tissue dysfunction contributes to the increase in hepatic HIF-1 
expression. To directly test whether obese adipocytes can signal to 
hepatocytes to increase HIF-1 expression, we incubated primary 
mouse hepatocytes with adipocyte-conditioned medium (ACM) 
collected from NCD/lean or HFD/obese WT adipocytes. As seen in 
Fig. 5H, hepatocytes incubated with ACM of HFD WT mice expressed 
higher levels of HIF-1 compared with hepatocytes incubated with 
ACM of NCD WT mice. Moreover, preincubation of HFD WT ACM 
with leptin-neutralizing antibodies blunted the effects to increase 
hepatocyte HIF-1 expression (Fig. 5H). Consistent with this, Dpp4 
expression was higher in hepatocytes incubated with HFD-ACM 
compared with NCD-ACM, and these effects were blocked by anti- 
leptin–neutralizing antibody treatment (Fig. 5I).
Because Hif1a mRNA expression and protein levels were increased in 
the liver of HFD mice compared with NCD mice, we tested whether obese 
ACM or leptin can also increase Hif1a mRNA expression. Incubation 
of hepatocytes with obese ACM or leptin for 3 hours did not increase 
Hif1a mRNA expression (fig. S5G), suggesting that obese ACM or leptin 
can increase HIF-1 protein levels mainly at the posttranscriptional level. 
However, 24-hour incubation with obese ACM increased Hif1a mRNA 
expression, and this effect was sensitive to the nuclear factor B 
Fig. 4. Deletion of hepatocyte HIF-2 does not affect obesity-induced glucose, glucagon, and insulin intolerance. (A) Liver Hif1a and Epas1/Hif2a mRNA levels 
(n = 4, 4, 6, and 9 mice per group). ***P < 0.0001 versus WT counterparts, #P < 0.05 versus NCD WT. (B) Body weight (n = 4, 5, 6, and 9 mice per group). (C) Fasting plasma 
insulin levels (n = 4, 5, 6, and 9 mice per group). (D) OGTTs and plasma insulin levels during OGTT (n = 4, 5, 6, and 9 mice per group). (E) IPITTs in HFD mice (n = 6 WT and 9 KO 
mice). (F) Glucagon tolerance tests in HFD mice (n = 11 WT and 8 KO mice). (G) Plasma DPP4 levels in HFD mice (n = 6 WT and 9 KO mice). (H) Liver DPP4 expression in HFD 
mice (n = 6 WT and 9 KO mice). (I) mRNA levels in liver (n = 4, 4, 6, and 9 mice per group). (J and K) Liver triglyceride (TG) (J) or nonesterified fatty acid (NEFA) (K) content 
(n = 6 WT and 9 KO mice). *P < 0.05 versus lane 3, ##P < 0.01 versus lane 1. For statistical analysis, one-way ANOVA with post hoc t tests between the individual groups was 
performed. All data are presented as means ± SEM.
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(NF-B) inhibitor Bay11-7082 but not to leptin-neutralizing antibody 
(fig. S5H). These results are consistent with previous reports that 
NF-B can transactivate Hif1a (49) and obese adipocytes release in-
flammatory cytokines stimulating NF-B (3). Together, these results 
suggest that obese adipocytes can signal to hepatocytes to increase 
Hif1a mRNA and protein expression, but only leptin mediates the latter.
Adipose tissue hypoxia leads to increased liver HIF-1 
and Dpp4 expression in obesity
Our results suggest that in obesity, dysfunctional adipocytes promote 
hepatic HIF-1 expression, causing increased hepatic DPP4 expression 
and first-pass GLP-1 inactivation. To test this concept of a multistep 
inter-organ communication (fig. S6) at the organismic level, we used 
HIF-1 adipocyte KO (HAKO) mice. Previously, we and others re-
ported that HAKO mice are protected from obesity-induced adipose 
tissue inflammation and dysfunction (3, 39, 44, 46, 47). Moreover, 
HFD HAKO mice exhibit several features of metabolically normal 
obese (MNO) subjects, distinct from metabolically abnormal (MAO) 
subjects, including decreased plasma leptin–to–adiponectin ratio 
(Fig. 5J) and plasma FFA levels upon insulin stimulation (39). Western 
blot analyses revealed that liver HIF-1 expression was decreased in 
HFD HAKO compared with HFD WT mice (Fig. 5K), with de-
creased Hif1a and Glut1 mRNA levels (Fig. 5L). To test whether the 
decrease in Hif1a mRNA expression is associated with decreased 
NF-B activity, we measured phosphorylated p65 NF-B levels in 
the liver of HFD WT and HAKO mice. As seen in fig. S7, phospho-
rylated p65 NF-B levels were reduced in HFD HAKO mouse liver 
compared with HFD WT controls. On the other hand, the decrease 
in liver HIF-1 expression was not associated with increased hepatic 
oxygen tension (Fig. 5M), consistent with the idea that obesity- 
induced decreased liver interstitial oxygen tension is not low enough 
to increase hepatocyte HIF-1 expression. HFD HAKO mice expressed 
decreased levels of hepatic Dpp4 compared with HFD WT controls 
(Fig. 5N). Consistent with these results, plasma intact/active GLP-1 
Fig. 5. Adipose tissue dysfunction induces increased liver HIF-1 expression. (A) Liver interstitial oxygen tension (n = 4 mice per group). *P < 0.05, ***P < 0.001 versus 
lane 1. (B) HIF- expression in primary hepatocytes incubated at different oxygen conditions for 3 hours. Arrowhead indicates nonspecific bands. (C) HIF- expression in 
primary hepatocytes incubated with different combinations of leptin (100 ng/ml), insulin (100 nM), palmitic acid (400 M), and fructose (5 mM) at three different concen-
trations of glucose (5, 10, and 21 mM) for 4 hours. (D) Dpp4 mRNA expression in WT and HIF-1 KO (HHKO) hepatocytes treated with leptin (100 ng/ml) + palmitic acid (PA) 
(400 M) for 24 hours. *P < 0.05. (E) HIF- expression in the liver of HFD WT mice treated with control immunoglobulin G (Ctl-IgG) or anti-leptin antibodies for 1 hour (n = 3 
and 5 mice, respectively). (F) Western blot analysis of HIF- and phosphorylated and total mTOR levels in primary hepatocytes incubated with different concentrations of 
leptin and/or adiponectin (AdipoQ) in the presence or absence of rapamycin (Rapa; 1 M) for 3 hours. (G) Dpp4 mRNA expression in primary hepatocytes incubated with 
leptin (Lep) ± adiponectin for 16 hours. **P < 0.01 versus lane 1, #P < 0.01 versus lane 2. (H and I) HIF-1 protein expression (n = 5, 2, 2, and 3) (H) and Dpp4 mRNA levels 
(n = 3 samples per group) (I) in primary hepatocytes incubated with ACM of NCD or HFD WT mice for 3 hours (H) or 18 hours (I). For leptin neutralization, HFD ACM was 
incubated with control IgG or anti-leptin antibodies for 1 hour at 4°C before incubation with hepatocytes. **P < 0.05 versus lane 1, #P < 0.01 versus lane 2, $P < 0.05 versus 
lane 3. (J) Plasma leptin and adiponectin levels (n = 2, 9, and 9 mice per group). ***P < 0.001 versus lane 1, ###P < 0.001 versus lane 2. (K) Liver HIF- expression. (L) Liver 
Hif1a and Glut1 mRNA expression (n = 10 mice per group). *P < 0.05. (M) Interstitial oxygen tension in the liver of HFD mice (n = 4 per group). (N) mRNA expression of Dpp4 
in the liver of HFD mice (n = 10 mice per group). *P < 0.05. (O) Plasma intact/active GLP-1 levels in 6-hour–fasted HFD mice before or 10 min after glucose oral gavage (n = 7 
mice per group). *P < 0.05. For statistical analysis, one-way (A, D, and G to J) or two-way (O) ANOVA with post hoc t tests between the individual groups or two-tailed 
unpaired t test (L and N) was performed. All data are presented as means ± SEM.
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levels were significantly increased in HFD HAKO mice compared 
with HFD WT controls (Fig. 5O). These changes were observed 
without a decrease of adipose tissue Dpp4 expression (fig. S8). To-
gether, these results suggest that adipocyte HIF-1 does not regu-
late adipocyte Dpp4 but can contribute to decreased incretin effects 
by regulating liver HIF-1 and Dpp4 levels.
DISCUSSION
Decreased circulating intact/active GLP-1 levels and incretin effects 
are important etiologic components of T2DM (22). Increased adi-
posity and insulin resistance are associated with this defect (23), but the 
underlying mechanisms are poorly understood. Here, we demon-
strate a previously unknown mechanism for how obesity decreases 
intact/active GLP-1 levels by triggering increased hepatic HIF-1 
expression and enhancing first-pass GLP-1 inactivation. We observed 
that the obesity- induced changes in circulating adipokines (i.e., 
increased leptin/adiponectin ratio) and FFA levels stimulate an 
isoform-selective increase in hepatic HIF-1 expression. This led 
to increased hepatic DPP4 expression and sinusoidal flow resist-
ance (with increased Edn1 expression and decreased extracellular 
adenosine levels). Deletion of hepatocyte HIF-1 blocked obesity- 
induced hepatic DPP4 expression and sinusoidal flow resistance, 
decreasing first-pass GLP-1 degradation and increasing plasma 
active GLP-1 and insulin levels upon glucose challenge. These changes 
were sufficient to cause improved glucose and glucagon tolerance 
in HFD/obese glucose- intolerant mice. Administration of a GLP-1 
receptor antagonist erased all of these beneficial effects on glycemic 
control, indicating that the effects of hepatocyte HIF-1 KO are 
mainly mediated by increased GLP-1 activity. Hepatocyte HIF-1 
KO did not change insulin sensitivity, hepatic steatosis, or inflam-
mation. Together, our results suggest that hepatocyte HIF-1 mediates 
obesity-induced multi-organ communication triggered by adipokine 
dysregulation, leading to impaired GLP-1 effects and glucose intol-
erance through increased first-pass GLP-1 inactivation.
While Dpp4 is ubiquitously expressed, several lines of evidence 
indicate that plasma intact/active GLP-1 levels are determined by 
specific spatiotemporal regulation of DPP4. For example, intact/
active GLP-1 levels and incretin effects are decreased with increased 
plasma DPP4 activity in T2DM patients (21), whereas the rate of 
intravenously injected exogenous GLP-1 elimination is comparable 
in normal and T2DM subjects in the fasted state (15). Oral admin-
istration of a low-dose DPP4 inhibitor, which is effective only in the 
intestinal area (but in peripheral blood), exerts full glucose lowering 
effects with a partial increase in intact GLP-1 levels (50). Recently, 
Mulvihill et al. (13) reported that, although DPP4 is highly expressed in 
both endothelial cells and enterocytes, deletion of enterocyte DPP4 does 
not change plasma active GLP-1 levels or glucose tolerance. In con-
trast, deletion of endothelial cell DPP4 increases plasma intact/active 
GLP-1 levels and improves oral glucose tolerance. Moreover, previously, 
it was reported that hepatic GLP-1 extraction accounts for ~44% of 
intact GLP-1 inactivation in pigs (38). These results raise the possibility 
that post-enteric (e.g., the portohepatic) DPP4 expression/activity is a 
critical determinant of circulating intact/active GLP-1 levels. However, it is 
not known whether this hepatic GLP-1 inactivation is increased in obesity.
In the present study, we found that glucose-stimulated intact/active 
GLP-1 levels were ~56% lower in peripheral plasma compared with 
portal plasma in normal lean mice. This difference was increased to 
~76% in HFD/obese mice, suggesting that obesity increases hepatic active 
GLP-1 elimination. In obese mice, Dpp4 expression was increased 
selectively in liver to hepatocytes and was not observed in nonpa-
renchymal cells. Moreover, a substantial amount of hepatocyte-produced 
DPP4 was accumulated on the plasma membrane in obesity. Given 
that newly produced GLP-1 is first introduced into the portal circu-
lation and that hepatic sinusoidal system represents a fenestrated 
capillary structure, it is plausible that increased liver DPP4 expres-
sion potentiates first-pass incretin hormone degradation in obesity. 
The increase in liver DPP4 expression was accompanied by decreased 
sinusoidal blood flow rate and velocity, which would provide more 
time for the increased liver DPP4 to mediate intact/active GLP-1 
degradation in obesity. In HHKO mice, the obesity-induced decrease 
in peripheral-to-portal active GLP-1 ratio was blocked with normal-
ization of the hepatic and plasma DPP4 levels and sinusoidal blood 
flow rate and velocity, suggesting that hepatocyte HIF-1 mediates 
those obesity-induced changes to increase first-pass active GLP-1 
degradation. How hepatic HIF-1 and DPP4 confers selectivity to 
postprandial GLP-1 regulation remains an open question.
In regard to the mechanism by which hepatocyte HIF-1 increases 
sinusoidal flow resistance, we observed that deletion of HIF-1 blocks 
obesity-induced increased Edn1 expression and decreases extracel-
lular adenosine levels. This is consistent with previous reports that 
show HIF-1–mediated induction of Edn1 and ADA expression/
activity (51, 52). ADA is a soluble protein readily detectable in blood 
circulation. Membrane-bound DPP4 binds to the soluble ADA, 
which facilitates its accumulation in the extracellular space where it acts 
to reduce local adenosine signaling (52). Therefore, obesity-induced 
increased liver membrane-bound DPP4 levels can also contribute 
to sinusoidal vasoconstriction by decreasing the local extracellular 
levels of adenosine.
Active GLP-1 levels were markedly higher in portal plasma com-
pared with peripheral plasma, emphasizing potential local hepatic 
GLP-1 effects. Despite the ongoing controversy about the presence 
of GLP-1 receptor in hepatocytes (53–55), it has been shown that 
GLP-1 receptor agonist treatment directly regulates hepatocyte me-
tabolism independent of its insulinotropic action (31–35, 56). Con-
sistent with these reports, we observed that GLP-1 treatment decreases 
HGP in cultured hepatocytes. Moreover, hyperglycemic clamp studies 
demonstrated that GLP-1 suppresses hepatic glucagon action in the 
presence of S961 and somatostatin. These results suggest that GLP-1 
can also suppress HGP independent of its insulinotropic action, which 
may be more important, particularly in insulin-resistant states. In 
obese HHKO mice, the decrease in hepatic DPP4 expression was 
associated with increased GLP-1–dependent HGP suppression. 
These results emphasize the importance of hepatic HIF-1–dependent 
DPP4 regulation in determining local and systemic GLP-1 effects 
and glucose metabolism. Further studies are required to determine the 
signaling pathway of how GLP-1 suppresses HGP in an insulin- 
independent fashion.
In HFD HAKO mice, increased hepatic HIF-1 expression and 
decreased interstitial oxygen tension were dissociated without changes 
in body weight. Moreover, incubation of hepatocytes at 2% oxygen 
(equivalent to oxygen tension in obese liver) did not increase HIF-1 
expression compared with 3% oxygen (equivalent to oxygen tension 
in lean liver). These results suggest that obesity-induced hepatic 
HIF-1 expression was not primarily due to decreased interstitial 
oxygen tension. Rather, treatment with hormones and nutrients that 
are increased in the blood circulation of obese mice interactively 
increased hepatocyte HIF-1 expression. The leptin + palmitic acid 
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combination synergistically increased HIF-1 expression to a maximal 
level compared to all other factors and combinations except adiponectin, 
which suppressed leptin-stimulated HIF-1 stabilization. These results 
suggest that the combinatorial changes in plasma leptin, adiponectin, 
and FFA levels are key to the increase in hepatic HIF-1 expression 
in obesity. To test whether inhibition of leptin is sufficient to rebalance 
the effect of these combinatorial changes to increase liver HIF-1 
expression, we used leptin-neutralizing antibodies. Administration of 
leptin-neutralizing antibodies markedly decreased obesity-induced 
hepatic HIF-1 expression. Moreover, increased adiponectin and 
decreased FFA levels in the plasma of HAKO mice were associated 
with decreased liver HIF-1 expression, even without changes in 
plasma leptin levels. Together, these results suggest that the combinatorial 
changes in plasma leptin, adiponectin, and FFA levels, but not the 
changes in single-factor (e.g., leptin) levels, are necessary for the full 
increase in liver HIF-1 expression in obesity.
Because leptin and adiponectin are adipocyte-specific hormones, 
and increased plasma FFA levels in obesity are mainly due to increased 
lipolysis in adipose tissue, it may be reasonable to conclude that adipose 
tissue dysfunction leads to increased hepatocyte HIF-1 expression and 
subsequent decrease in incretin effects. These results are consistent 
with a previous report that adipocyte HIF-1 KO mice exhibit increased 
plasma active GLP-1 levels in obesity (57). It was also reported that 
obesity-induced hepatic DPP4 production can stimulate adipose 
tissue inflammation and insulin resistance through an endocrine 
mechanism (58, 59). Therefore, it is likely that adipose tissue 
inflammation/dysfunction and hepatic HIF-1–mediated DPP4 
expression can constitute a feed-forward mechanism to exaggerate 
the disease pathology.
Here, we report a previously unknown pathway that obesity 
enhances plasma GLP-1 inactivation and impairs glucose tolerance 
by inducing HIF-1–dependent liver DPP4 expression and sinusoidal 
flow resistance. Because hepatocyte-specific deletion of HIF-1 
exerted beneficial effects to improve glucose tolerance without changing 
body weight in mice, it is reasonable to question whether the hepatic 
HIF-1–DPP4 pathway is associated with metabolic health in obese 
humans (e.g., MAO versus MNO). In addition, it is possible that 
liver-specific inhibition of either or both HIF- isoforms may be 
sufficient to improve T2DM and nonalcoholic fatty liver diseases 
in humans. While strongly supported by mouse genetics, all of these 
hypotheses remain to be tested in humans in the future.
MATERIALS AND METHODS
Study design
The current study was initially designed to (i) determine the effect 
of obesity on liver oxygen tension and HIF-1 and HIF-2 expression 
and (ii) define what role hepatocyte HIF-1 and HIF-2 play in 
obesity-associated changes in liver inflammation, steatosis, insulin 
resistance, and glucose intolerance. Initial results showed that, in 
HFD/obese states without massive liver damage and fibrosis, hepatocyte 
HIF-1 is not necessary for liver inflammation and insulin resistance 
but can reduce glucose-stimulated insulin secretion with decreased 
plasma active GLP-1 levels. The following studies were designed to 
(i) define what role hepatocytes HIF-1 and HIF-2 play in obesity- 
induced decreased incretin effects (glucose-stimulated insulin secretion) 
and plasma active GLP-1 degradation, (ii) define what role hepatocyte 
HIF-1 plays in obesity-induced liver microhemodynamics and 
portal blood pressure, and (iii) determine how obesity confers an 
isoform-selective induction of liver HIF-1 expression. For in vivo 
studies, age-matched Cre− Hif1afl/fl or Hif2afl/fl littermates were 
caged together with Cre+ KO mice and were used as WT controls. 
Animal numbers for each study type were determined by the investigators 
on the basis of data from previous similar experiments or from pilot 
studies. Results were confirmed in at least two separate cohort 
mouse experiments. For in vitro studies, at least three biological 
replicates were used. For in vivo experiments and biochemical 
assays, mouse or sample identities were not blinded, but in most 
cases, the sequence of analyzed tubes and mice was randomized.
Animals
To generate adipocyte- or hepatocyte-specific HIF-1 or HIF-2 
KO mice, Hif1afl/fl or Hif2afl/fl mice were crossed to mice expressing 
Cre recombinase under the control of the Adiponectin or Albumin 
promoter, respectively. To obtain relatively equal numbers of KO 
and WT littermates, breeding pairs were set up by mating Hif1afl/fl(or 
Hif2afl/fl):Cre+ and Hif1afl/fl(or Hif2afl/fl):Cre− mice. All mice were 
on the C57BL6 background and housed in colony cages in 12-hour 
light/12-hour dark cycles. For HFD studies, 7- to 8-week-old male 
mice were subjected to 60% HFD for 10 weeks or the indicated time 
periods (Research Diets Inc., catalog no. D12492). Glucose and 
insulin tolerance tests were performed as described previously 
(24, 39, 60). For glucagon tolerance, mice were fasted for 6 hours 
and intraperitoneally injected with glucagon (15 g/kg), and blood 
glucose levels were measured at indicated time points. For the 
glucose or glucagon tolerance tests with ex9 pretreatment, mice 
were fasted for 5.5 hours. After measuring blood glucose levels at 
time −30 min, mice were intraperitoneally injected with 5 g of ex9. 
Thirty minutes later (time 0), blood glucose levels were measured at 
indicated time points. Hyperglycemic clamp experiments were 
designed and optimized for measuring liver-specific GLP-1 effects 
and sensitivity. For these studies, mice were surgerized for jugular 
vein cannulation. After 5 days of recovery, mice were fasted for 
6 hours and infused with d-[3H]glucose (PerkinElmer) plus somatostatin 
(6 g/kg per min) for 60 min. After tracer equilibration, blood samples 
were collected at −10 and 0 min (basal). Glucose (50% dextrose) and 
tracer (5 Ci/hour) plus somatostatin (6 g/kg per min), glucagon 
(50 ng/kg per min), S961 (5 nmol/kg per min), and active GLP-1 (20 ng/kg 
per min) were then infused into the jugular vein. GLP-1 stimulates 
 cell insulin secretion and suppresses plasma insulin clearance 
and alpha cell glucagon secretion; however, we wanted to measure 
liver-specific GLP-1 effects independent of insulinotropic action. 
Even with a relatively high-dose somatostatin infusion, plasma 
insulin levels were significantly increased by GLP-1 infusion to 
supraphysiological levels. Therefore, we also infused S961 insulin 
receptor antagonist along with somatostatin and glucagon during 
the glucose clamp studies. Because S961 is a competitive inhibitor of 
insulin receptor, the dose of S961 was determined experimentally 
as a minimal dose that blocks insulin effects at the experimental 
condition. Since exogenous glucagon infusion in the presence of S961 
and somatostatin caused hyperglycemia, to obtain proper window for 
HGP suppression by GLP-1, glucose levels were clamped at 600 mg/dl. 
Blood glucose levels were monitored every 10 min, and glucose 
infusion rate was adjusted as necessary. Steady-state blood glucose 
levels were maintained at 600 ± 10 mg/dl for the last 20 min or longer, 
without changing glucose infusion rate, and blood samples were 
collected at 110 and 120 min (clamped). Specific activity and insulin 
levels were measured from the basal and clamped plasma samples. All 
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animal procedures were performed in accordance with an Institutional 
Animal Care and Use Committee–approved protocol and the research 
guidelines for the use of laboratory animals of the University of California 
San Diego or the Korea Advanced Institute of Science and Technology.
Tissue interstitial oxygen tension
The oxygen partial pressure was measured using carbon fiber electrodes 
(Carbostar-1, Kation Scientific, Minneapolis, MN). The tip of the 
electrode was coated with 5% Nafion (Sigma-Aldrich, St. Louis, MO) to 
increase oxygen specificity. The process consisted of three individual 
Nafion coats. The microelectrodes were polarized at −0.8 V relative 
to a silver-silver chloride reference electrode (Cypress Systems, 
Lawrence, KS). Oxygen measurements were performed after 3-hour 
fasting using the two-electrode system (working and reference electrode), 
and the current generated was measured with a potentiostat and 
electrometer (Keithley model 610C; Cleveland, OH). The microelectrodes 
are calibrated at 37°C with 0, 5, 10, and 21% O2 gases (Airgas, Los 
Angeles, CA), and tissues were superfused (0.1 ml/min) with physiological 
Krebs salt solution. The tissue was maintained at 35° to 37°C by the 
heated Krebs solution. The solution was spread on the tissue as a 
thin film, drained into a platter, and drawn off by suction. The solution 
was equilibrated with 95% N2 and 5% carbon dioxide, which maintained 
the superfusate at a pH of 7.4 and minimized oxygen delivery to the 
tissue from the atmosphere. Oxygen measurements were made by 
penetrating the tissue with the microelectrode tip. The reference 
electrode was placed in the bath, and the microelectrode was placed 
in a shielded holder and advanced toward the measurement site 
with a micromanipulator. A long-working distance ×10 Leitz objective 
was used to direct the electrode to the measurement site. Before 
measurements, the electrode tip was immersed in the supernatant 
suffusion solution and the current was registered. The supernatant 
suffusion solution was set as 0 mmHg reference point. Upon introduction 
into the tissue, the microelectrodes responded with a time constant 
that was estimated to be of the order of 10 s. A stable reading was 
obtained within 30 s, and upon reaching the current plateau value, 
the electrode was extracted from the tissue and the tip was maintained 
within the suffusing saline solution. The unit of tissue O2 tension 
was converted from mmHg to % later. Oxygen tension was measured 
at >30 different regions of each mouse liver. Appearance rate denotes 
chances for observing indicated O2 tension in a random spot of the 
mouse liver.
Microhemodynamics
A video image–shearing method was used to measure vessel diameter 
(D). Changes in arteriolar and venular diameter from baseline were 
used as indicators of a change in vascular tone. Arteriolar and venular 
centerline velocities were measured on-line using the photodiode 
cross-correlation method (Photo Diode/Velocity Tracker Model 102B, 
Vista Electronics, San Diego, CA). The measured centerline velocity 
(V) was corrected according to vessel size to obtain the mean red blood 
cell velocity. Blood flow (Q) was calculated from the measured values 
as Q =  × V (D/2)2.
Histology
Immunohistochemistry analyses and  cell mass were performed as 
described previously (60). Images were captured using a NanoZoomer 
slide scanner system with NanoZoomer Digital Pathology software 
(Hamamatsu) or confocal fluorescence microscopy. Microscopic 
images were analyzed using ImageJ software.
Plasma/serum and tissue hormone concentration 
and content
Plasma insulin (ALPCO), C-peptide (ALPCO), DPP4 (Thermo Fisher 
Scientific), active and total GLP-1 (ALPCO), GIP (Crystal Chem), and 
glucagon (Mercodia) levels were measured by enzyme-linked immuno-
sorbent assay (ELISA) in accordance with the manufacturers’ instruction. 
To prevent degradation of active GLP-1 or active GIP by DPP4 during 
or after sample collection, DPP4 inhibitor (Millipore, catalog no. DPP4-010) 
was briefly added to each tube after sample collection. Plasma and tissue 
DPP4 activity was measured with a fluorometric assay kit (BioVision). 
Pancreatic insulin content was determined as described previously (60). 
Briefly, whole pancreas from each mouse was ground in 10 ml of acidic 
ethanol using a Polytron tissue homogenizer (Kinematica), and insulin 
levels were measured by ELISA in the tissue lysates. Total insulin 
content was calculated by multiplying the lysate insulin concentration, 
dilution factor, and total volume of the tissue lysate.
Gluconeogenic activity in primary hepatocytes
To isolate primary hepatocytes, mice were infused through the inferior 
vena cava with a calcium-free Hepes-phosphate buffer (pH 7.4) for 
10 min followed by a collagenase solution (Liberase TM, Roche) for 
10 min. The digested livers were excised, and hepatocytes were 
collected and washed five times in buffer by centrifuging at 70g for 
5 min. Cells were further purified by centrifugation (2400g for 10 min) 
over a Percoll density gradient (1.06 g/ml). Primary mouse hepatocytes 
were allowed to attach for 6 hours on collagen-coated plates in Williams’ 
Medium E (Life Technologies, catalog no. 12551-032) fortified with 
nonessential amino acids, GlutaMAX (Life Technologies, catalog 
no. 35050-061), antibiotics, 10% fetal bovine serum, and dexamethasone 
(10 nM) and cultured overnight in the same medium without serum. 
Cultures were then washed in Hepes phosphate-salt-bicarbonate 
(HPSB) buffer (10 mM Hepes, 4 mM KCl, 125 mM NaCl, 0.85 mM 
KH2PO4, 1.25 mM Na2HPO4, 1 mM MgCl2, 1 mM CaCl2, and 15 mM 
NaHCO3) containing 0.2% FFA-free bovine serum albumin (BSA) 
and incubated in the same buffer containing GLP-1 (100 nM), 
Exendin-4 (30 nM), insulin (10 nM), and/or glucagon (10 ng/ml) 
and substrates for 3 hours in a 5% CO2 incubator. 14C-pyruvate 
(2 mM, 0.5 Ci pyruvate per incubation) was used as substrate. In-
cubations were carried out in 0.5-ml buffer in 24-well plates containing 
0.25 million cells per well. At the end of incubation, the buffer solutions 
were transferred to 1.7-ml microcentrifuge tubes and added with 
0.25 ml of 5% ZnSO4 and 0.25 ml of 0.3 N Ba(OH)2 suspensions to 
each tube, followed by addition of 0.5 ml of water. After centrifuga-
tion, supernatants were transferred to a fresh set of tubes and assayed 
for radiolabeled glucose released into the medium by separation of 
radiolabeled glucose by mixed-bed ion exchange resins, AG 501-X8 
resins (Bio-Rad). Two hundred milligrams of resins was added to 
each tube, vortexed intermittently for 15 min, and centrifuged, and 
the supernatants were transferred to scintillation vials for counting 
radioactivity. Cells on the plates were dissolved in 1 N NaOH for 
protein estimation.
ADA activity and extracellular adenosine  
level measurements
Primary mouse hepatocytes cultured in six-well plates were washed 
with HPSB buffer containing 0.2% FFA-free BSA, 2 mM glucose, and 
2 mM pyruvate and then incubated in the same buffer for 3 hours in a 
5% CO2 incubator. Supernatant and cell pellets were collected and 
saved for further assays. Extracellular adenosine levels were determined 
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in the hepatocyte-conditioned media using a colorimetric assay kit 
(BioVision, catalog no. K327). Plasma membrane fraction of the cell 
pellets (Abcam, catalog no. ab65400) was subjected to ADA activity 
assays using a colorimetric assay kit (BioVision, catalog no. K321).
Western blot analysis
Tissues and cells were lysed in lysis buffer [20 mM tris-HCl (pH 7.4), 
100 mM NaCl, 1.5 mM MgCl2, and 0.1% (v/v) NP-40] containing a 
protease and phosphatase inhibitor cocktail (Roche Diagnostics) 
and then centrifuged at 13,000 rpm for 15 min at 4°C. The supernatants 
were separated in SDS–polyacrylamide gel electrophoresis gels (Bio-Rad) 
and electrotransferred to polyvinylidene difluoride membranes. The 
membranes were blocked for 2 hours in tris-buffered saline with 
Tween 20 (TBST) [10 mM tris-HCl and 0.1% Triton X-100 (pH 7.4)] 
containing 5% BSA and then incubated with specific antibodies at 
4°C overnight: HIF-1 (Abcam, catalog no. ab-2185), HIF-2 (Novus 
Biologicals, catalog no. NB100-122), heat shock protein 90 (HSP90) 
(Santa Cruz Biotechnology, catalog no. SC-13119), actin (Sigma-Aldrich, 
catalog no. A2228), and vinculin (Cell Signaling Technology, catalog 
no. 4650). After washing with fresh TBST, the membrane was incubated 
with secondary antibody conjugated with horseradish peroxidase 
specific to rabbit or mouse immunoglobulin G (1:5000 dilution; 
Jackson ImmunoResearch Laboratories) and visualized using the 
enhanced chemiluminescence system (Millipore, catalog no. WBKLS0050) 
followed by autoradiography or Bio-Rad ChemiDoc XRS+ imaging 
system. The intensity of the bands in the autoradiograms was measured 
using ImageJ software.
Quantitative real-time polymerase chain reaction
Total RNA was extracted with TRIzol reagent (Invitrogen) or RNeasy 
Mini Kit (Qiagen, Hilden, Germany). Synthesis of complementary 
DNA (cDNA) was performed using the High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA). Quantitative 
real-time polymerase chain reaction (PCR) was performed using 
Power SYBR Green PCR Master Mix (Applied Biosystems). Primer 
sequences are available upon request.
Liver cell sorting
To isolate primary hepatocytes and nonparenchymal cells, livers were 
perfused and digested using pronase/collagenase method. Single- cell 
suspensions were centrifuged at 50g for 5 min to pellet the hepatocyte 
fraction. The remaining nonparenchymal cell fraction was collected and 
used for immediate analysis or subjected to further fractionation. After 
gradient centrifugation (15% Nycodenz), hepatic immune cells were 
sorted (FACSAria, BD Biosciences) or analyzed by flow cytometry 
(FACSCanto, BD Biosciences; FlowJo software, Treestar). For flow 
cytometry analysis, cells were stained with LIVE/DEAD Aqua to ex-
clude dead cells and blocked with CD16/32 monoclonal antibody 
(Thermo Fisher Scientific, catalog no. 14-0161-81). The fluorescence- 
labeled antibodies against CD45 (eBioscience, catalog no. 83-0451042) 
for leukocytes; CD11b (eBioscience, catalog no. 11-012-82), F4/80 
(eBioscience, catalog no. 25-4801-82), and Ly6C (Thermo Fisher Scientific, 
catalog no. 12-5932-80) for hepatic macrophages; or CD3 (eBioscience, 
catalog no. 56-0032-82), CD4 (eBioscience, catalog no. 17-0041-82), and 
CD8 (BioLegend, catalog no. 100722) for lymphocytes were used.
Statistical analysis
The results are shown as means ± SEM. Statistical analyses were 
performed by Student’s t test (for comparison between two groups) 
or one- or two-way analysis of variance (ANOVA) (for comparison 
between multiple groups or in two groups at multiple time points, 
respectively, with post hoc t tests between the individual groups); 
P < 0.05 was considered significant.
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